PATENT CLAIM ANALYSIS

Application Number: 16040981
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["424", "186100"]

Abstract:
The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Claim (Index 136):
A method comprising administering to a subject a respiratory virus vaccine that comprises\n (a) an isolated messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame encoding an antigenic human parainfluenza virus type 3 (hPIV3) Fusion (F) protein; and (b) an isolated mRNA polynucleotide comprising an open reading frame encoding an antigenic human metapneumovirus (hMPV) F protein, formulated in at least one lipid nanoparticle that comprises a molar ratio of 20-60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid, wherein the isolated mRNA polynucleotide of (a) and the isolated mRNA polynucleotide of (b) are not self-replicating RNA, and wherein the vaccine is administered to the subject in an effective amount to induce an immune response in the subject.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 95.0
- Lexical Diversity: 1.25
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15674599', '15674591', '15674585', '15674569', '16006526']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8261121535435003
- 35 USC 102 Novelty (BERT): 0.8622899027469968
- Combined Prediction Score: 0.82972992846385
- Mean Citation Score: 760.816598
- Max Citation Score: 1268.1471
- Similarity Product: 1241.9249795595108

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test